HLB Pharmaceutical Co. Ltd - Asset Resilience Ratio
HLB Pharmaceutical Co. Ltd (047920) has an Asset Resilience Ratio of 11.61% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how HLB Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. Check HLB Pharmaceutical Co. Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down HLB Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of HLB Pharmaceutical Co. Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩19.49 Billion | 11.61% |
| Total Liquid Assets | ₩19.49 Billion | 11.61% |
Asset Resilience Insights
- Moderate Liquidity: HLB Pharmaceutical Co. Ltd has 11.61% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
HLB Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio
Compare HLB Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940 |
Drug Manufacturers - Specialty & Generic | 9.11% |
Annual Asset Resilience Ratio for HLB Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for HLB Pharmaceutical Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 13.92% | ₩21.99 Billion ≈ $14.90 Million |
₩157.93 Billion ≈ $107.03 Million |
-4.38pp |
| 2023-12-31 | 18.30% | ₩25.87 Billion ≈ $17.53 Million |
₩141.35 Billion ≈ $95.79 Million |
+0.99pp |
| 2022-12-31 | 17.32% | ₩24.62 Billion ≈ $16.69 Million |
₩142.18 Billion ≈ $96.35 Million |
-2.69pp |
| 2021-12-31 | 20.01% | ₩25.54 Billion ≈ $17.31 Million |
₩127.63 Billion ≈ $86.49 Million |
-51.12pp |
| 2020-12-31 | 71.13% | ₩79.25 Billion ≈ $53.71 Million |
₩111.42 Billion ≈ $75.51 Million |
+40.87pp |
| 2019-12-31 | 30.25% | ₩14.04 Billion ≈ $9.51 Million |
₩46.39 Billion ≈ $31.44 Million |
+21.30pp |
| 2018-12-31 | 8.95% | ₩3.26 Billion ≈ $2.21 Million |
₩36.42 Billion ≈ $24.68 Million |
-5.79pp |
| 2017-12-31 | 14.74% | ₩5.87 Billion ≈ $3.98 Million |
₩39.85 Billion ≈ $27.00 Million |
-14.17pp |
| 2016-12-31 | 28.91% | ₩11.92 Billion ≈ $8.08 Million |
₩41.24 Billion ≈ $27.95 Million |
+27.30pp |
| 2015-12-31 | 1.61% | ₩399.39 Million ≈ $270.66K |
₩24.85 Billion ≈ $16.84 Million |
-8.95pp |
| 2014-12-31 | 10.56% | ₩2.26 Billion ≈ $1.53 Million |
₩21.43 Billion ≈ $14.53 Million |
-- |
About HLB Pharmaceutical Co. Ltd
HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, anti… Read more